Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies, Inc. SEC filings document the public-company record for a biotechnology diagnostics issuer with Nasdaq-listed common stock and tradeable warrants. The filings identify the company as an emerging growth company and smaller reporting company and include disclosures tied to CyPath® Lung, laboratory services, operating performance, and securities registration activity.
Recent filings include Form 8-K reports for financial results, Regulation FD presentation materials, product and clinical-case announcements, and annual meeting voting results. The record also covers governance matters such as director elections and equity incentive plan amendments, along with S-1 registration materials describing securities being registered and related issuer classifications.
Roberto Rios, a director of bioAffinity Technologies, Inc. (BIAF), filed an initial Form 3 disclosing beneficial ownership of 833 shares of the company's common stock. The event requiring the statement occurred on 08/12/2025 and the Form 3 bears a signature date of 09/25/2025. The filing indicates direct ownership and does not disclose any derivative securities or indirect holdings.
bioAffinity Technologies (BIAF) Form 3 — initial ownership disclosure. John J. Oppenheimer, listed as a Director, filed an initial Form 3 reporting that no securities are beneficially owned by him as of the event date 08/12/2025. The form shows the reporting relationship, the issuer symbol BIAF, and a signature dated 09/25/2025.
bioAffinity Technologies, Inc. is registering a primary offering of up to 729,927 shares of common stock, up to 729,927 pre-funded warrants, placement agent warrants for up to 21,898 shares, and up to 751,825 shares underlying these warrants. The company estimates net proceeds of about $3.4 million, assuming $4.0 million in gross sales at an assumed price of $5.48 per share. Shares outstanding would increase from 1,375,102 to 2,105,029 if all common shares (and no pre-funded warrants) are sold. The best-efforts offering has no minimum, so proceeds may be significantly lower, and there is no escrow. The company recently completed a 1-for-30 reverse stock split and is working to regain Nasdaq compliance on minimum bid price and stockholders’ equity.
bioAffinity Technologies, Inc. filed an S-1 registration disclosing an assumed public offering price of $5.48 per share and pro forma capital impacts tied to that offering. The company reported a historical net tangible book value per share of $(1.30) as of June 30, 2025. Pro forma adjustments related to the offering increase net tangible book value by $2.06 to a pro forma as adjusted net tangible book value per share of $0.76. The filing shows a reported dilution to new investors of $4.72 per share. Additional disclosed items include conversion mechanics for Series B Convertible Preferred Stock (conversion price noted as $6.90 per share) and line items for additional paid-in capital and total capitalization figures included in the filing tables.
bioAffinity Technologies, Inc. filed a Current Report on Form 8-K disclosing a corporate action: the company announced a Reverse Stock Split and furnished a related press release dated September 17, 2025. The filing also includes a Certificate of Amendment to the Certificate of Incorporation as Exhibit 3.1, and the press release is furnished as Exhibit 99.1. The 8-K indicates these documents are part of the company's report of a material event but does not provide the split ratio or detail any effects on shares outstanding, shareholder approvals, or listing status within the disclosed text.
bioAffinity Technologies, Inc. filed an amended prospectus to register up to 32,495,628 shares of common stock for resale by existing investors and other selling stockholders. These resale shares include stock issuable upon conversion of Series B preferred stock and upon exercise of several sets of warrants, including Private Warrants, Inducement Warrants, May 2025 Warrants and advisor and placement agent warrants.
The company itself is not selling shares in this offering and will not receive proceeds from stockholder resales, but may receive cash if investors convert the preferred stock or exercise the registered warrants. The filing stems from recent financings and warrant inducement transactions completed in August 2025 and related anti-dilution adjustments to May 2025 warrants.
bioAffinity develops noninvasive diagnostics such as its CyPath® Lung test for early-stage lung cancer and continues to advance additional lung disease diagnostics and oncology therapeutic research while operating as an emerging growth and smaller reporting company.